What is Pathos AI?
Pathos AI operates at the intersection of artificial intelligence and precision medicine, focusing on the re-engineering of drug development processes. By leveraging advanced computational models, the company aims to accelerate the discovery and validation of therapeutic candidates. This AI-enabled biotechnology approach allows Pathos AI to form strategic partnerships with established pharmaceutical entities, effectively bridging the gap between complex biological data and actionable clinical outcomes. The company is currently positioned as a high-growth enterprise, utilizing its recent capital to scale operations and expand its pipeline of precision-targeted treatments.
How much funding has Pathos AI raised?
Pathos AI has raised a total of $427M across 2 funding rounds:
Series C
$62M
Series D
$365M
Series C (2024): $62M with participation from New Enterprise Associates, Builders VC, Lightbank, and Revolution Growth
Series D (2025): $365M led by Builders VC, Growth Revolution, New Enterprise Associates, and Lightbank
Key Investors in Pathos AI
New Enterprise Associates
Established in 1977 and headquartered in Menlo Park, California, New Enterprise Associates is a venture capital firm focused on helping entrepreneurs build businesses.
Builders VC
Builders VC is a venture capital firm focused on modernizing antiquated industries by investing in innovative technologies and solutions across sectors like healthcare.
Lightbank
Lightbank is an investment firm based in Chicago, IL, focusing on funding innovative startups and providing strategic guidance to scale operations.
What's next for Pathos AI?
Following this major enterprise-level funding, Pathos AI is poised to accelerate its clinical development programs and enhance its proprietary technology stack. The strategic allocation of capital will likely focus on expanding research capabilities and deepening collaborative efforts with global pharmaceutical partners. As the company transitions into a more mature operational phase, the focus will shift toward validating its AI-driven insights in large-scale clinical trials, aiming to reduce the time-to-market for life-saving therapies. Investors remain optimistic that this infusion of resources will enable Pathos AI to maintain its competitive edge in the rapidly evolving landscape of digital health and precision medicine.
See full Pathos AI company page
